European Journal of Cancer
Volume 42, Issue 12 , Pages 1875-1880 , August 2006

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

  • I. Duran

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • ,
  • L.L. Siu

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • Corresponding Author InformationCorresponding author: Tel.: +1 416 946 2911; fax: +1 416 946 4467.
    • ,
  • A.M. Oza

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • ,
  • T.-B. Chung

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Diagnostic Imaging, Toronto, Canada
    • ,
  • J. Sturgeon

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • ,
  • C.A. Townsley

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • ,
  • G.R. Pond

      Affiliations

    • Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9
    • ,
  • L. Seymour

      Affiliations

    • National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    • ,
  • M. Niroumand

      Affiliations

    • Mount Sinai Hospital, Department of Respirology, Toronto, Canada

Received 9 November 2005 ,Revised 17 March 2006 ,Accepted 21 March 2006.

References 

  1. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16(4):525–537
  2. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19(56):6680–6686
  3. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci USA. 2001;98(18):10320–10325
  4. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–135
  5. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1995;55(9):1982–1988
  6. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004;77(8):1215–1220
  7. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343(3):225–226
  8. Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343(24):1815–1816
  9. Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant. 2001;16(1):18–20
  10. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8(3):249–258
  11. Ha L. The rapamycin derivative RADOO1 in oncology: What is the endpoint? In: AACR-NCI-EORTC Internal Conference. Molecular Cancer and Cancer therapeutics; 17–21 November 2003; Boston, MA; 2003. p. 259–60.
  12. Mita MM, Goldston ML, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of AP 23573, an mTOR inhibitor administered IV daily×5 every other week in patients with refractory or advanced malignancies. In: Proc Am Soc Clin Oncol; 2004; New Orleans: Meeting proceedings American Society of Clinical Oncology; 2004.
  13. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91(8):1420–1424
  14. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002;62(21):6141–6145
  15. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7(6):1758–1764
  16. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62(17):5027–5034
  17. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61(4):1527–1532
  18. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12):2336–2347
  19. Baselga JFP, Gil M, et al. Phase 2-3 study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol. 2004;23:13;Abstract 544
  20. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–918
  21. Tabernero JR, Burris H, Casado E, Macarulla T, Jones S, Dimitrijevic S, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol. 2005;23(16s):193s;Abstract 3007
  22. Chawla SP, Chua V, Menendez LR, Eilber FC, Eckardt JJ, Daly ST, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. Proc Am Soc Clin Oncol. 2005;23(16s):833s;Abstract 9068
  23. Feldman E, Roboz G, Yee K, Curcio T, Rivera VM, Albitar M, et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Proc Am Soc Clin Oncol. 2005;23(16s):592s;Abstract 6631
  24. Mahalati K. Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation. 2000;69:1581
  25. Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72(5):787–790
  26. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005;23(23):5314–5322
  27. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23(23):5294–5304
  28. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent Temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23(23):5347–5356

PII: S0959-8049(06)00354-6

doi: 10.1016/j.ejca.2006.03.015

European Journal of Cancer
Volume 42, Issue 12 , Pages 1875-1880 , August 2006

Article Tools

* Image Usage & Resolution